anonymous
Guest
anonymous
Guest
Got a leak from RBM that they’re looking at mirror territory reps on which to cut and retain. CMRs not safe either. RBMs looking over their backs too. They’re on thin ice as the reps. Start looking for jobs
Got a leak from RBM that they’re looking at mirror territory reps on which to cut and retain. CMRs not safe either. RBMs looking over their backs too. They’re on thin ice as the reps. Start looking for jobs
Got a leak from RBM that they’re looking at mirror territory reps on which to cut and retain. CMRs not safe either. RBMs looking over their backs too. They’re on thin ice as the reps. Start looking for jobs
This is speculation, even from the supposed RBM. RBMs don't pick who to cut and retain. That would make for an instant discrimination suit. However, they will be asked to rank employees on certain metrics such as tenure, performance, geography to territory, and a bunch of others. Then all of this information is randomized, typically by an outside vendor to avoid bias, and ensures that everyone from every segment gets cut: old, young, top performers, bottom performers, all races and all genders. This is how cuts are conducted to ensure no liability. Keeps it fair and ensures no bias and or cherrypicking favorites. Or they cut everyone, including all of management.
Maybe that's what they mean by Reduce It.
My manager thinks we have until Dec. before they start reducing the field force. Anyone hearing something else?
Seriously though.... do you REALLY want to sell a Cholesterol drug anyway??? One of the most saturated markets in the industry.They don’t know anything more than us. Any second now, I’m expecting the “Wait for your manager” call. American market is done. I was optimistic but after this appeal, Vascepa is done as far as promotion spending in the US.
until the generics hit the market, we have jobs. After that occurs, they will evaluate their options. Of course, cuts will happen but I would assume we have at least until the end of the year before we see cuts or get word of potential cuts. It all depends on how fast a generic comes and with the capacity to legitimately compete with us in terms of supply. How deep the cuts are all speculation. This company has several ways forward in the US to still create value and have active promotion. My guess is we see employment closer to that first round of reduce it hires when we went from 100 to 250 before the other expansions. Territories get bigger, no partners, etc. But its all speculation. If you think they let this go completely, you're wrong. Too much at stake. We can compete with a generic in several ways. Plenty of companies have done this but you have to trim the fat to keep the revenues in tact. Disagree all you want. Go look for a job if you want. Many will not be retained when the smoke clears. How long that takes is a different question that no one has the answer to yet.